# DESCRIPTION

## BACKGROUND OF THE INVENTION

- introduce GI symptoms in ASD children
- summarize studies on GI symptoms in ASD children
- describe inflammatory pathology in ASD children
- discuss features of GI disease in ASD children
- analyze inflammatory infiltrate in mucosa
- describe mucosal cytokine profiles in ASD children
- distinguish lesions in ASD children from IBD
- discuss disturbances in mucosal function
- describe intestinal microflora in ASD children
- summarize consensus report on GI disorders in ASD
- discuss immunologic and inflammatory activity
- describe molecular characterization of inflamed tissue
- discuss gene expression profiling of biopsy-derived tissue
- identify biomarker panel for distinguishing IBD
- discuss need for molecular characterization of ASD children

## SUMMARY OF THE INVENTION

- introduce method of diagnosing GI disorder
- describe measuring biomarker levels
- detect polymorphisms in biological sample
- introduce method of diagnosing ASD
- describe kit for diagnosis of GI and/or ASD
- provide additional embodiments of kit
- discuss various embodiments of methods

## DETAILED DESCRIPTION

- introduce ASDIC markers
- list methods using ASDIC biomarkers
- discriminate inflammatory disorders
- diagnose ASD-associated IBD variant
- refine disease diagnosis and management

### DEFINITIONS

- define technical and scientific terms
- introduce articles "a" and "an"
- define "about" in measurable values
- define "abnormal" in organisms and tissues
- define "alteration" as increase or decrease
- define "amplification" of polynucleotide sequences
- define "analyte" as substance undergoing analysis
- define "assessing" as measurement or determination
- define "autism spectrum disorder (ASD)"
- define "biomarker" as characteristic of biological process
- define "capture reagent" as binding nucleic acid or polypeptide
- define "decreases" as negative alteration
- define "detect" as identifying presence or level
- define "detectable" as moiety rendering molecule detectable
- define "disease" as state of health with deteriorating condition
- define "disorder" as state of health with less favorable condition
- define "alleviated" as reduced severity of disease or disorder
- define "effective amount" of compound as beneficial effect
- define "encoding" as property of nucleotide sequences
- define "expression" as transcription and translation
- define "fragment" as portion of polypeptide or nucleic acid molecule
- define "genotype" as genetic composition
- define "IGF2BP1 nucleic acid molecule" as polynucleotide encoding IGF2BP1
- define "IL2RA nucleic acid molecule" as polynucleotide encoding IL2RA
- define "TNFRSF12A nucleic acid molecule" as polynucleotide encoding TNFRSF12A
- define "increases" as positive alteration
- define "instructional material" as publication or recording
- define "marker" and "epigenetic marker" as distinguishing substance
- define "marker profile" as characterization of expression levels
- define "measuring" or "detection" as assessing presence or level
- define "patient", "subject", "individual" as animal or cells
- define "nucleic acid or oligonucleotide probe" as binding target sequence
- define "polynucleotide" as chain of nucleotides
- define "protein" or "peptide" as compound of amino acid residues
- define "quantitative trait" as phenotype attributed to genes
- define "quantitative trait locus (QTL)" as DNA sequence regulating trait
- define "expression quantitative trait loci (eQTLs)" as genomic loci regulating expression
- define "reference" as standard or control condition
- define "sample" or "biological sample" as biological material
- define "single nucleotide polymorphism (SNP)" as DNA sequence variation
- define "specifically binds" as compound or antibody recognizing polypeptide
- define "substantially identical" as polypeptide or nucleic acid molecule with high identity
- define "target nucleic acid molecule" as nucleic acid or biomarker to be detected
- define "therapeutic" treatment as diminishing or eliminating sign or symptom
- define "treating a disease or disorder" as preventing or alleviating sign or symptom
- define "therapeutically effective amount" as preventing or treating disease or disorder
- define "variant" as polynucleotide or polypeptide sequence differing from wild-type
- define "hybridize" as pairing to form double-stranded molecule
- define "stringency" conditions for hybridization and washing steps

### DESCRIPTION

- relate invention to ASD-associated inflammatory disorder
- compare gene expression profiles in GI symptomatic ASD children and non-ASD control groups
- identify biomarkers for ASD-associated inflammatory disorder screening and diagnosis
- describe potential pharmaceutical targets
- outline method of screening for Autism Spectrum Disorder
- obtain nucleic acid sample from cells of a patient
- perform nucleic acid analysis to obtain gene expression analysis data set
- compare data set to control data set corresponding to gene ensemble of differentially expressed genes
- indicate autism spectrum disorder upon observing statistically significant differential gene expression
- obtain nucleic acid sample from cells of the gastrointestinal tract of a patient
- observe expression profile of at least 2, 3, 4, 5, 6, 7, 8, 9 or
- 10 genes whose expression is shown to be dysregulated in autism spectrum disorders
- perform method on a plurality of individuals and categorize based upon similarities or differences in their gene expression profiles
- observe and/or collect and/or store expression profile(s) using a computer system
- create electronically searchable library of profiles
- include individual's gene expression data in combination with other diagnostic data
- relate invention to one or more biomarkers of ASD
- detect differentially expressed transcripts (DETs) in samples obtained from subjects with ASDIC
- compare to samples obtained from non-disease control subjects, subjects with Crohn's disease, or subjects with ulcerative colitis
- detect biomarker to have decreased expression in a subject with ASD compared to a control sample
- detect biomarker to have increased expression in a subject with ASD compared to a control sample
- list biomarkers in Table 6
- list biomarkers in Table 9
- use biomarker to detect a gastrointestinal disorder and/or autism spectrum disorder in a subject
- describe altered gene expression of transcripts indicating presence of a gastrointestinal disorder in ASD individuals
- capture biomarkers on a biochip array
- detect analytes by a variety of detection methods
- use mass spectrometry, and in particular, SELDI
- use optical methods, including fluorescence, luminescence, chemiluminescence, absorbance, reflectance, transmittance, birefr
- use electrochemical methods, including voltametry and amperometry
- use radio frequency methods, including multipolar resonance spectroscopy
- perform quantitative MS to measure serum peptide marker
- perform MS in an automated or semi-automated format
- link MS to a liquid chromatography device or gas chromatography device
- measure multiple markers
- use pattern recognition to detect patterns formed by multiple markers
- correlate expression levels of particular nucleic acids or polypeptides with a gastrointestinal disorder and/or autistic spectrum disorder
- measure levels of polypeptide using immunoassay, ELISA, western blotting and radioimmunoassay
- use oligonucleotides or longer fragments derived from a nucleic acid sequence
- use antibodies that bind a polypeptide
- monitor expression of a polynucleotide or polypeptide of interest
- correlate a 1.5, 2, 3, 4, 5, or 6-fold change in the level of a marker
- inform treatment selection based on diagnosis
- treat with corticosteroids, immunomodulators, 5-aminosalicylic acid preparations, cytokine specific antagonists, dietary restrictions
- treat with antimicrobials, probiotics, and supplemental digestive enzymes
- target therapies that decrease or eliminate the expression of any of the nucleic acid molecules or polypeptides
- use combination of markers to provide greater predictive value than single markers alone
- describe PCR method
- introduce thermostable DNA polymerase
- define 3′→5′ exonuclease activity
- list examples of proofreading enzymes
- describe long range PCR
- introduce sequencing
- describe Sanger method
- describe pyrosequencing
- introduce real-time PCR
- describe 5′ nuclease probes
- describe TaqMan probes
- describe molecular beacons
- describe FRET hybridization probes
- introduce primer extension
- describe RFLP
- introduce mass spectrometry
- describe ESI
- describe ESI/MS/MS
- describe SIMS
- describe LD-MS
- describe LDLPMS
- describe MALDI-TOF-MS
- introduce hybridization
- define hybridization
- describe high stringency conditions
- describe medium stringency conditions
- describe low stringency conditions
- describe label detection
- describe fluorescent label
- describe enzyme tag
- describe solid phase hybridization
- describe solution hybridization
- introduce kits
- describe kit components
- describe capture reagent
- describe primer or probe
- describe enzymes for amplification
- describe dNTPs/rNTPs and buffers
- describe labeled deoxynucleotides
- describe detection reagents
- describe associated instructions
- describe treatment agents
- describe carrier means
- describe container means
- describe packaging

## EXPERIMENTAL EXAMPLES

- introduce experimental examples

### Example 1

- introduce ASDIC study
- describe study design
- present subject demographics
- outline case selection and biopsy procurement
- describe control biopsy procurement
- detail microarray and data analysis
- explain sample preparation
- describe microarray hybridization
- outline qPCR validation
- present data analysis methods
- describe pair-wise analysis
- outline principal component analysis
- explain hierarchical clustering analysis
- describe expression quantitative trait loci analysis
- present demographics of cases and controls
- describe ASDIC samples
- describe non-ASD samples
- outline principal component analysis results
- describe ileal mucosa gene expression profiles
- describe colonic mucosa gene expression profiles
- outline pairwise comparisons
- describe IPA analysis
- present diseases and disorders findings
- present physiological system development and function findings
- present top canonical pathway involvement findings
- describe differentially-expressed transcripts in ileal mucosa
- describe differentially-expressed transcripts in colonic mucosa
- outline validation of microarray results
- describe qPCR validation results
- present eQTL analysis results
- describe functional enrichment analysis
- present gene ontology analysis results
- describe pathway analysis results
- outline transcription factor analysis
- present biological function analysis results
- summarize study findings
- analyze DETs in ASDIC ileal mucosa
- identify down-regulated and up-regulated genes
- associate with gastrointestinal disease and inflammatory response
- associate with humoral immune response and tissue morphology
- associate with digestive system development and function
- identify canonical pathways
- analyze DETs in Crohn's disease ileal mucosa
- associate with inflammatory disease and immune response
- associate with immune cell trafficking and cell-mediated immune response
- identify canonical pathways
- analyze DETs in ulcerative colitis ileal mucosa
- associate with cardiovascular disease and connective tissue disorders
- associate with nervous system development and function
- identify canonical pathways
- analyze DETs in ASDIC colonic mucosa
- associate with gastrointestinal disease and neurological disease
- associate with behavior and organ development
- identify canonical pathways
- analyze DETs in Crohn's disease and ulcerative colitis colonic mucosa
- introduce ulcerative colitis group
- compare inflamed colonic mucosa with non-inflamed mucosa
- analyze down-regulated transcripts
- analyze up-regulated transcripts
- identify diseases and disorders
- identify physiological system development and function
- identify significant canonical pathways
- compare DETs in ASDIC sub-groups
- identify DETs unique to ASDIC cases
- analyze biological functions
- identify significant metabolic and signaling pathways
- verify transcripts by quantitative real-time PCR
- compare gene expression profiles in ASDIC cases
- identify DETs unique to LNH+ileitis group
- analyze diseases and disorders
- analyze physiological system development and function
- identify significant canonical pathways
- characterize inflamed GI biopsy tissue
- distinguish ASDIC from non-inflamed controls
- compare ASDIC with IBD and non-inflamed controls
- analyze overlap between ASDIC and IBD gene expression profiles
- identify unique DETs in ASDIC tissue
- analyze gene expression in terminal ileum mucosal tissue
- analyze gene expression in colonic mucosal tissue
- identify disease categories and biological pathways
- analyze impact of ileitis on gene expression in ASDIC cases
- identify DETs unique to LNH+ileitis samples
- analyze biological pathways
- summarize gene expression patterns
- analyze relationships between DETs
- discuss methodological aspects
- compare with previous reports
- discuss factors influencing gene expression
- analyze distribution of gene expression profiles
- discuss underlying inflammatory process
- compare eQTL in ASD associated ileocolitis and IBD
- identify eQTL associations in terminal ileum and colon tissues

